A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Add Yahoo as a preferred source to see more of our stories on Google. Unlike typical glaucoma treatments that slow progression, this approach aims to rejuvenate the retinal ganglion cells that die ...

The idea that cells could be reset emerged from decades of research in regenerative medicine. The field traces back to 1962, ...

In this excerpt from “We Are As Gods: A Survival God for the Age of Abundance,” authors Peter H. Diamandis and Steven Kotler ...

Life runs on information. In living systems, that information takes two main forms: the genome and the epigenome. The genome stays mostly stable. The epigenome, however, constantly shifts, shaped by ...

For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in.

The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Beyond headlines and promises of eternal youth, advances in transplants, epigenetic clocks, and cellular reprogramming are redefining aging to help people live longer — and, above all, healthier. Some ...